Next Article in Journal
Antimycobacterial Activities of Hydroxamic Acids and Their Iron(II/III), Nickel(II), Copper(II) and Zinc(II) Complexes
Next Article in Special Issue
The Role of Stakeholders’ Understandings in Emerging Antimicrobial Resistance: A One Health Approach
Previous Article in Journal
Heterogeneous Habitats in Taiga Forests with Different Important Values of Constructive Species Changes Bacterial Beta Diversity
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 11
Issue 10
10.3390/microorganisms11102610
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Multidrug-Resistant and Extensively Drug-Resistant Escherichia coli in Sewage in Kuwait: Their Implications

by
Mahdi A. Redha
,
Noura Al Sweih
and
M. John Albert
*
Department of Microbiology, College of Medicine, Kuwait University, Jabriya 46300, Kuwait
*
Author to whom correspondence should be addressed.
Microorganisms 2023, 11(10), 2610; https://doi.org/10.3390/microorganisms11102610
Submission received: 11 September 2023 / Revised: 17 October 2023 / Accepted: 20 October 2023 / Published: 23 October 2023
(This article belongs to the Special Issue Antimicrobial Resistance and Multidrug-Resistant Bacteria in Infectious Patients)
Review Reports Versions Notes

Abstract

:
In Kuwait, some sewage is discharged into the sea untreated, causing a health risk. Previously, we investigated the presence of pathogenic E. coli among the 140 isolates of E. coli cultured from the raw sewage from three sites in Kuwait. The aim of the current study was to characterize the antimicrobial resistance of these isolates and the implications of resistance. Susceptibility to 15 antibiotic classes was tested. Selected genes mediating resistance to cephalosporins and carbapenems were sought. ESBL and carbapenemase production were also determined. Two virulent global clones, ST131 and ST648, were sought. A total of 136 (97.1%), 14 (10.0%), 128 (91.4%), and 2 (1.4%) isolates were cephalosporin-resistant, carbapenem-resistant, multidrug-resistant (MDR), and extensively drug-resistant (XDR), respectively. Among the cephalosporin-resistant isolates, ampC, blaTEM, blaCTX-M, blaOXA-1, and blaCMY-2 were found. Eighteen (12.9%) samples were ESBL producers. All carbapenem-resistant isolates were negative for carbapenemase genes (blaOXA-48, blaIMP, blaGES, blaVIM, blaNDM, and blaKPC), and for carbapenemase production. Resistance rates in carbapenem-resistant isolates to many other antibiotics were significantly higher than in susceptible isolates. A total of four ST131 and ST648 isolates were detected. The presence of MDR and XDR E. coli and global clones in sewage poses a threat in treating E. coli infections.

1. Background

Sewage undergoes treatment to reduce microbial contamination before discharge into the environment [1,2]. In Kuwait, 75% of sewage is treated, the treated effluent is used for landscaping and irrigation purposes, and the sludge after primary treatment is used as manure for growing plants and to remediate the soil. The remaining 25% of the sewage is discharged into the sea untreated, resulting in coastal water contamination [3,4]. The coastal sea is used for recreational purposes (swimming, boating, and fishing) in Kuwait, and sewage disposal takes place within a kilometer of recreational areas. Although treatment of sewage can greatly reduce microbial content, the treated effluent is still not fully safe and can be a threat to human health as it can harbor pathogenic and drug-resistant bacteria [1,2,5].
Escherichia coli, a fecal indicator, is a predominant organism of the sewage [6]. It is a causative agent of both intestinal and extra-intestinal infections due to diarrheagenic E. coli (DEC) and extra-intestinal pathogenic E. coli (ExPEC), respectively [7]. E. coli is also used as a sentinel organism for the surveillance of antimicrobial resistance (AMR) [8]. Cephalosporin and carbapenem antibiotics are important therapeutic agents for the treatment of E. coli infections [9,10]. E. coli clones, such as the sequence types, ST131 and ST648, are multi-drug resistant and highly virulent and have spread globally causing urinary tract infections and bloodstream infections [11]. These clones belong to certain Clermont phylogenetic groups [12,13]. In a previous study [14], we published our findings on 140 E. coli isolates cultured from raw sewage in Kuwait for DEC, ExPEC, and phylogenetic groups. In the present report, we present additional information on these E. coli isolates about resistance to a range of antimicrobial agents, including selected genes encoding extended-spectrum β-lactamases (ESBLs) and carbapenemases. In addition, even though there are numerous global E. coli clones, we sought two of them, ST131 and ST648, because of their worldwide distribution, encompassing North America, Europe, Asia, and Africa, and their ease of detection via PCR assays [15]. This study has provided insights into the problem of drug resistance in E. coli in the community emanating from sewage. The previous study focused on virulence properties, and the current study focuses on drug resistance including that in selected global clones. The potential implications of human exposure to multidrug-resistant E. coli in sewage, for the treatment of infections, are also discussed in this manuscript.

2. Methods

E. coli culture. E. coli isolates originated from raw sewage samples. Raw sewage was sampled once a month for 12 months from three sites in Kuwait during May 2018–April 2019. A total of 140 different E. coli isolates were cultured from 36 sewage samples. The sampling method and characterization of E. coli, including DEC, ExPEC, and Clermont phylogenetic groups, have been described previously [14]. The isolates stocked in tryptic soy broth (Oxoid, Basingstoke, Hampshire, UK) with 15% glycerol at −80 °C were subcultured onto MacConkey agar (Oxoid). Single colonies, after reconfirmation as E. coli in the API-20E test (bioMerieux, 69280 Marcy l’Etoile, France), were used for the current study. There were 3 isolates of DEC (2 atypical enteropathogenic E. coli (aEPEC) isolates, J28 and H164, and 1 enterotoxigenic E. coli (ETEC) isolate, H51), and 14 isolates of ExPEC [14]. The remainder of the isolates were neither diarrheagenic pathogens nor extra-intestinal pathogens and, therefore, can be considered non-pathogenic.
The disk diffusion test was conducted following the CLSI guidelines [16] against 28 antibiotics belonging to 15 classes. Susceptibilities to polymyxins were tested by growth inhibition in a broth containing the antibiotic (see later test details) (Supplementary Table S1). E. coli colonies grown on brain–heart infusion agar (Oxoid) at 37 °C for 20 h were emulsified in saline to obtain a 0.5 MacFarland turbidity standard comparable to the density of a bacterial suspension with 5 × 105 cfu/mL. This suspension was used to inoculate Mueller–Hinton agar (Oxoid), which was later overlaid with antibiotic discs. The plate was incubated at 37 °C for 18 h, and the growth inhibition zones were measured. Quality control organisms for the disc diffusion test included E. coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, and Staphylococcus aureus ATCC 25923.
The isolates were classified as resistant, intermediate resistant, or susceptible according to the zone sizes for all antibiotics except for polymyxins (HiMedia, Mumbai, Maharastra, India; Supplementary Table S1). Multidrug-resistant (MDR) bacteria are resistant to at least one agent in three or more antimicrobial categories, extensively drug-resistant (XDR) bacteria are resistant to at least one agent in all but two or fewer antimicrobial categories, and pan-resistant (PR) bacteria are resistant to all agents in all antimicrobial categories [17]. Resistant and intermediate-resistant strains were traditionally considered clinically resistant.
Selected bacteria were tested against additional antibiotics to fulfill the definition of XDR bacteria [17]. These included ceftaroline (anti-methicillin-resistant Staphylococcus aureus cephalosporin), cefazolin (non-extended-spectrum cephalosporin), and tigecycline (glycylcycline). Susceptibilities to ceftaroline (Allergan, Austin, TX, USA) and tigecycline (Sigma-Aldrich, St. Louis, MI, USA) (an MIC value of ≥0.5 mg/L for both) [18] were determined by the broth dilution method. Mueller–Hinton broth (Oxoid) was used as the medium dispensed in tubes. The starting concentration of the antibiotic used was 0.1 mg/L with increments of 0.1 mg/L in subsequent serial tubes. The bacterial inoculum was prepared as in the disc diffusion test. The tubes were incubated at 37 °C for 20 h before reading the results. The lowest concentration of the antibiotic that completely inhibited bacterial growth was taken as the MIC (minimum inhibitory concentration). Susceptibility to cefazolin (HiMedia) (a zone diameter of 20–22 mm for intermediate resistance and a zone diameter of ≤19 mm for resistance) [16] was performed by the disc diffusion method.
A Rapid Polymyxin NP test was conducted to determine the resistance to polymyxin B or polymyxin E (colistin). The test was performed according to the procedure of Nordmann et al. [19]. For negative control, ATCC 25922 E. coli was used, and for the positive control, a clinical isolate of Morganella morganii resistant to both polymyxin B and colistin was used. Resistance of test bacteria was indicated by growth in polymyxin-containing broth through a color change of a pH indicator.
Isolates having specific resistance patterns in susceptibility tests were further analyzed for specific genes encoding resistance by PCR assays (Supplementary Table S2). The dominant β-lactamase genes, blaOXA-1, blaCMY-2, ampC, blaCTX-M, blaTEM, and blaSHV [20], were sought in isolates resistant to one or more of the β-lactams (cefepime, cephalothin, ceftazidime, cefoxitin, cefotaxime, ceftriaxone). If isolates were resistant to one or more of the carbapenems (ertapenem, meropenem, imipenem), they were screened for the dominant genes encoding carbapenem resistance (blaNDM, blaOXA-48, blaKPC, blaIMP, blaVIM, blaGES) [21,22].
Many PCR assays were performed to detect drug-resistant genes. Some procedures that were common to all PCR assays—preparation of template DNA, agarose gel electrophoresis, and detection of amplicons—are described below. A loopful of E. coli growth from MacConkey agar was boiled in PCR-grade sterile distilled water in an Eppendorf tube (Eppendorf, Hamburg, Germany) for 10 min. The supernatant containing the DNA was used as the template (~25 ng/μL as estimated via NanoDrop method (Thermo Scientific, Waltham, MA, USA). The following reagents were added in a PCR tube (Eppendorf) to obtain a 10 µL reaction volume: 2 µL of master mix (Solis BioDyne, Teaduspargi, Tartu, Estonia), 1 µL of forward primer (10 pmol), 1 µL of reverse primer (10 pmol), 5 µL of PCR-grade sterile distilled H2O, and 1 µL of diluted DNA (25 ng/µL). This PCR mix was then placed in a thermal cycler (Applied Biosystems, San Francisco, CA, USA) with the desired cycles. The primer sequences, cycling conditions, and amplicon sizes in PCR assays are shown in Supplementary Table S2. The amplicons were separated by agarose gel electrophoresis. The concentration of the agarose in the gel was 1.0% (for products ˃ 800 bp), 1.5% (for products 200–800 bp), and 2% (for products < 200 bp). The gel incorporated with ethidium bromide was run in Tris-Borate-EDTA buffer at a voltage of 100 V for ~40 min and photographed under UV light.
An ESBL NDP test was conducted, as described previously [23], for the expression of ESBL. This test is based on the hydrolysis of the β-lactam ring of cefotaxime, which generates a hydroxyl group, resulting in acidification of the medium with a change in color from red to yellow. The prevention of hydrolysis and, hence, the change in color of the medium by the addition of tazobactam indicates a positive test. A wild-type E. coli strain was used as the negative control, and a Klebsiella pneumoniae strain positive for CTX-M-15 was used as the positive control [24].
A Rapidec Carba NP test was used according to the manufacturer’s instructions (BioMerieux) for carbapenemase production. The substrate for carbapenemase was imipenem. The broth with imipenem also contained zinc to detect metallo-β-lactamase. Carbapenemase production will result in imipenem hydrolysis, resulting in color change in the medium due to a pH indicator. A broth devoid of imipenem was used as the negative control and a strain of K. pneumoniae-positive NDM-5 and OXA-244 was used as the positive control [25].
Global clones. Specific PCR assay was conducted on ExPEC isolates belonging to group B2 to detect ST131 clones [26]. ExPEC isolates belonging to group F were screened for three genes: icd, gyrB, and uidA. The ST648 clone was positive for the first two genes but negative for the third gene [27]. The primers for the assays are included in Supplementary Table S2.
Statistical tests. The difference in the proportions was tested via the chi-squared test or Fisher’s exact test. A p-value ≤ 0.05 was considered statistically significant.

3. Results

Antibiotic susceptibility. The data on antibiotic susceptibility are shown in Table 1. A high number (≥50%) of these isolates were resistant to cefepime, cephalothin, cefotaxime, streptomycin, amoxiclav, piperacillin, piperacillin/tazobactam, ampicillin, and tetracycline. The highest number of isolates was resistant to piperacillin, and the lowest number of isolates were resistant to fosfomycin. The high prevalence of resistance was influenced by the relatively high numbers of intermediate-resistance isolates.
The resistance of the isolates to the number and classes of antibiotics is shown in Table 2. Many isolates showed resistance to between 6 and 15 antibiotics. The number of cephalosporin-resistant E. coli isolates and carbapenem-resistant (CR) E. coli isolates were 136 (97.1%) and 14 (10.0%), respectively. Of the 28 antibiotics tested, one isolate each showed resistance to up to 20, 22, and 23 antibiotics. A total of 128 (91.4%) isolates were multidrug-resistant, being resistant to between 3 and 12 classes of antibiotics. One isolate each was resistant to 13 and 14 classes of antibiotics. These two isolates were resistant to additional antibiotics tested—ceftaroline, cefazolin, and tigecycline.
The resistance patterns of ExPEC, DEC, and global clones are shown in Supplementary Table S3. As the number of isolates in each category was small, a statistical comparison was not possible. A lack of resistance was found to one antibiotic (meropenem) in ExPEC; nine antibiotics (ertapenem, meropenem, imipenem, gentamicin, amikacin, fosfomycin, chloramphenicol, polymyxin B, and colistin) in DEC; and six antibiotics (meropenem, imipenem, gentamicin, fosfomycin, polymyxin B, and colistin) in global clones, ST131 and ST648. Both aEPEC isolates (J28 and H164) were resistant to four of the cephalosporins (cephalothin, ceftazidime, cefoxitin, and cefotaxime) and ampicillin. In addition, H164 was resistant to cefepime, ceftriaxone, aztreonam, streptomycin, all the penicillins with β-lactamase inhibitors, piperacillin, both antifolates, ciprofloxacin, azithromycin, and sulfafurazole. The ETEC isolate (H51) was susceptible to 25 of the 28 antibiotics tested. The isolate showed resistance to the other three antibiotics—cephalothin, cefotaxime, and tetracycline.
Differences in the resistance of carbapenem-resistant (CR) versus carbapenem-susceptible (CS) E. coli to other antibiotics are shown in Supplementary Table S4. In general, CR E. coli were more resistant than CS E. coli. This difference was significant for 10 antibiotics—cefepime, ampicillin, ampicillin/sulbactam, trimethoprim, co-trimoxazole, tetracycline, ciprofloxacin, fosfomycin, chloramphenicol, and colistin.
The prevalence of resistance in ExPEC and non-ExPEC (including nonpathogenic E. coli and DEC) to all except two antibiotics was similar with no significant differences. However, the higher prevalence of resistance in ExPEC for ceftriaxone and colistin was significant (Supplementary Table S5).
For PCR assays, six β-lactamase genes were targeted in a total of 136 samples that were resistant to ≥ one of the β-lactams (cefepime, cephalothin, ceftazidime, cefoxitin, cefotaxime, or ceftriaxone). All these samples were positive for ampC (100%). The next two frequent genes detected were blaTEM and blaCTX-M, being present in 54 (39.7%) and 22 (16.2%) isolates, respectively. The least frequent genes were blaOXA-1, which was present in nine (6.6%) samples, and blaCMY-2, which was present in eight (5.9%) samples. None of the isolates were positive for the blaSHV gene. One aEPEC (J28) and the ETEC (H51) isolates were positive for ampC only, while the other aEPEC (H164) had three genes: ampC, blaCMY-2, and blaTEM. For the 14 ExPEC that were all resistant to one or more of the cephalosporins, the following genes were present: blaOXA-1 in two (14.3%) isolates, blaCMY-2 in one (7.1%) isolate, blaCTX-M in five (35.7%) isolates, blaTEM in one (7.1%) isolate, and ampC in all fourteen (100.0%) isolates.
The ESBL NDP test showed that 18/136 (13.2%) isolates were ESBL-positive (Supplementary Table S6). All these isolates had no zone of inhibition in the disk diffusion test against the cefotaxime disk. All isolates were positive for ampC, 16 were positive for blaCTX-M, 6 were positive for blaTEM, 5 were positive for blaOXA-1, and 1 was positive for blaCMY-2. All were resistant to cephalothin, ceftazidime, cefotaxime, and cefepime. Sixteen isolates were additionally resistant to ceftriaxone and four to cefoxitin. None of the DECs were ESBL-positive, while 6 (42.9%) of the 14 ExPEC isolates were ESBL producers.
For the Rapidec Carba NP test, all 14 samples that were resistant to a carbapenem (the number of resistant strains will appear as 17 in Table 1 and Supplementary Table S5 because one isolate was resistant to both ertapenem and meropenem, and another was resistant to all three meropenems) were tested, and all were negative.
Global clones. Since the ST131 clone belongs to the phylogenetic group B2 of ExPEC, all eight isolates of group B2 were tested, and one isolate (Z222) was positive. Since the clone ST648 belongs to group F of ExPEC, all five isolates of this group were tested, and three isolates (J211, H250, and J295) were positive. The resistance and ESBL production of these clones are shown in Supplementary Table S7.

4. Discussion

The water samples studied in different countries have been found to be contaminated with E. coli due to the disposal of improperly treated sewage [28].
We found that 91.4% of our E. coli isolates were multidrug-resistant and three isolates (2.1%) were resistant to ≥20 antibiotics. Further analysis showed that two isolates (1.4%) were resistant to 13–14 classes of antibiotics, in addition to ceftaroline, cefazolin, and tigecycline, which fulfills the definition of XDR bacteria [17]. The three additional antibiotics were not included in the initial screening of all isolates. Having found two isolates as possible candidates for extreme drug resistance, we tested these isolates against the additional antibiotics to fulfill the definition of extreme drug resistance. High resistance rates (>50%) to cephalosporins, in addition to ampicillin, piperacillin, and amoxiclav, were found. This correlates with the results of previous studies from Kuwait on clinical isolates [29,30,31,32]. Additionally, we found that most of the isolates were resistant to piperacillin/tazobactam, streptomycin, and tetracycline. It should be noted that isolates that exhibited intermediate resistance to most of the tested antibiotics are now considered as “susceptible, increased exposure category” when there is a high likelihood of therapeutic success if exposure to the antibiotic is increased by increasing the dosing regimen [33]. Inappropriate prescribing of antibiotics and self-medication are widespread risk factors in Kuwait [34]. These would have contributed to the high prevalence of resistance in E. coli.
All our E. coli isolates had the ampC gene. This gene is typically present in the chromosome with minimal constitutive enzyme production, although it can be hyper-expressed due to gene amplification or mutations creating a strong promoter. AmpC-type β-lactamases may also be carried on plasmids that mediate broad-spectrum cephalosporin resistance [35,36,37]. Further, 39.7% of E. coli isolates were blaTEM-positive, 16.2% had blaCTX-M, 6.6% and 5.9% were positive for blaOXA-1 and blaCMY-2, respectively, and none were blaSHV-positive. The ESBL producers in our study were 12.9%, which is similar to the finding of Dortet et al. [38]. Furthermore, 16 (88.9%) of 18 ESBL-positive isolates were blaCTX-M-positive, while blaTEM, blaOXA-1, and blaCMY-2 genes were present in 6 (33.3%), 5 (27.8%), and 1 (5.6%) isolates, respectively. All our isolates that were positive for the ESBL NDP test had no zone of inhibition to cefotaxime (in the disk diffusion test), the substrate used in the ESBL NDP test. It should also be noted that the blaCTX-M gene, which is found in most of our ESBL producers, confers resistance to cefotaxime. This correlation between ESBL NDP test positivity, cefotaxime resistance, and blaCTX-M positivity was also observed by Dortet et al. [38].
There are reports of CR E. coli causing human infections in Kuwait [39,40,41]. Fourteen (10.0%) of our E. coli isolates were CR, indicating a moderate prevalence of resistance to this class of antibiotics. CR strains were significantly more resistant to other antibiotics compared to CS strains. These findings correlate with those of other studies [42,43,44]. However, none of the CR E. coli isolates possessed carbapenemase genes, a finding like that of Zowawi et al. [45]. Performing PCR assays for selected genes may give false negative results as other known genes or novel genes could be missed. One way to confirm carbapenemase production is by performing a Rapidec Carba NP test that detects carbapenemase production regardless of specific genes. We determined that none of our 14 CR strains were positive in this test, thus confirming the absence of carbapenemase genes [46]. Other reported mechanisms of carbapenem resistance are efflux pumps [47] and loss of or reduction in the permeability of outer membrane proteins [48,49], which could be present in our isolates.
Among the DEC, the two aEPECs were multidrug-resistant and possessed cephalosporin resistance genes. The lone ETEC was comparatively more susceptible. None of the DEC isolates was an ESBL producer. DEC isolated from sewage treatment plants or environmental water samples from other countries showed resistance to many antibiotics [50,51,52,53].
It was noted that there were no significant differences between ExPEC isolates and non-ExPEC isolates in the resistance rates except for resistance to two antibiotics. ExPEC cultured from sewage effluent or river water receiving sewage in South Africa or Mexico showed different patterns of resistance to antibiotics [50,51,52,53].
The ST131 lineage has more virulence genes compared to other E. coli strains and exhibits diverse mechanisms of antibiotic resistance [54,55,56,57]. It has been found in clinical samples and in wastewater and recreational water samples [58]. This clone carries the β-lactamase gene, blaCTX-M [59]. In addition, some strains might carry blaTEM [60,61], blaSHV [61,62], ampC [60], or other genes [60]. In the strains of this clone, CTX-M is usually coproduced with OXA-1 and an aminoglycoside-modifying enzyme encoded by the aac(6′)-Ib-cr gene that confers resistance to aminoglycosides and fluoroquinolones [55,63]. CTX-M was shown to enhance the survival of the bacterium [13,64]. ST131 was previously reported in Kuwait in clinical samples [65].
The other global clone, ST648, is known to harbor resistance genes such as blaCTX-M, blaCMY-2, blaOXA-48, and blaNDM [66]. This ST has also been isolated from fresh and environmental water samples [67,68,69] and from wastewater samples [70,71,72].
A total of 4 out of 14 of our ExPEC isolates (28.6%) were of ST131 and ST648 lineages. They were resistant to 6–13 classes of antibiotics and possessed resistant genes, and two were ESBL producers. All four of these ExPEC isolates had a combination of three ExPEC genes [14], suggesting a high virulence in these clones, as found by other authors [54,55,56,57].
Thus, the reuse of water from treated sewage and the discharge of untreated sewage into the seas pose a threat to human health in Kuwait via the finding of pathogenic (DEC and ExPEC) and resistant E. coli in raw sewage. The characteristics of these bacteria appear to reflect those of the isolates from human infections in the community. To our knowledge, such a comprehensive study of sewage E. coli for drug resistance to a wide range of antimicrobial agents, including resistance mechanisms to extended-spectrum beta-lactams and carbapenems, and global clones has not been conducted before in Kuwait or in the region. The finding of MDR and XDR E. coli isolates constitutes a threat to public health as they can cause infections that are difficult to treat. A limitation of our study is that we have not thoroughly investigated the mechanisms of resistance. Leading experts have declared that antimicrobial resistance is a global health emergency [73]. The spread of drug-resistant bacteria in the community increases the risk of death for common infections, such as urinary tract infections, for which E. coli is the predominant pathogen [74]. Emerging technologies, such as network pharmacology and functional genomics, in association with in vivo imaging platforms, offer great promise for new antimicrobial discovery [75]. The recent discovery of some antibiotics—fabimycin [76] and teixobactin [77]—offers new hope for treating multi-resistant superbugs. Our findings also have relevance to one health. One health is an approach that recognizes that the health of people is closely connected to the health of animals and our shared environment [78]. The microorganisms in the sewage are derived from humans, animals, plants, and soil, and have an impact on these constituents. Thus, the presence of antibiotic-resistant E. coli in sewage in Kuwait has implications for one health.

5. Conclusions

The analysis of sewage in Kuwait has shown the presence of MDR and XDR E. coli and virulent E. coli global clones in sewage. Since some raw sewage is discharged into coastal waters that are used for recreational activities, the presence of MDR and XDR E. coli and global clones in the coastal waters poses a danger to human health, which may result in difficult-to-treat infections.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/2076-2607/11/10/2610/s1, Table S1: Antibiotics that were used with their resistance or susceptible zone diameters (mm). Table S2: List of primers used and the cycling parameters for each PCR assay; Table S3: Distribution of resistance in ExPEC (n = 14), DEC (n = 3) and global clonesa (n = 4); Table S4: Differences in resistance of CR E. coli (n = 14) and CS E. coli (n = 126) to other antibiotics; Table S5: Differences in resistance of ExPEC (n = 14) versus non-ExPEC (n = 126) isolates; Table S6: Cephalosporin resistance, ESBL genes, and production of ESBL; Table S7: Resistance patterns of, and ESBL production by, global clones. References [26,27,79] are cited in the Supplementary Materials.

Author Contributions

M.J.A. obtained funding, designed the study, and wrote the manuscript. M.A.R. performed the laboratory work under the supervision of M.J.A. and N.A.S. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by a Kuwait University Research Sector grant (no. YM04/19).

Informed Consent Statement

This work did not involve human or animal samples.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Acknowledgments

We thank the people involved in the collection of sewage samples in the Underworlds Project from which the E. coli isolates originated.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflict of interest.

References

  1. Hendricks, R.; Pool, E.J. The effectiveness of sewage treatment processes to remove faecal pathogens and antibiotic residues. J. Environ. Sci. Health A Tox Hazard Subst. Environ. Eng. 2012, 47, 289–297. [Google Scholar] [CrossRef] [PubMed]
  2. Al-Gheethi, A.A.; Efaq, A.N.; Bala, J.D.; Norli, I.; Abdel-Monem, M.O.; Ab Kadir, M.O. Removal of pathogenic bacteria from sewage-treated effluent and biosolids for agricultural purposes. Appl. Water Sci. 2018, 8, 74. [Google Scholar] [CrossRef]
  3. Aleisa, E.; Alshayji, K.A.; Al-Jarallah, R. Residential wastewaters treatment system in Kuwait. In Proceedings of the 2nd International Conference on Environmental Science and Technology IPCBEE; IACSIT Press: Singapore, 2011; Volume 6, pp. 285–289. [Google Scholar]
  4. Aleisa, E.; Alshayji, K. Analysis on reclamation and reuse of wastewater in Kuwait. J. Eng. Res. 2019, 7, 1–13. [Google Scholar]
  5. Anastasi, E.M.; Matthews, B.; Gundogdu, A.; Vollmerhausen, T.L.; Ramos, N.L.; Stratton, H.; Ahmed, W.; Katouli, M. Prevalence and persistence of Escherichia coli strains with uropathogenic virulence characteristics in sewage treatment plants. Appl. Environ. Microbiol. 2010, 76, 5882–5886. [Google Scholar] [CrossRef]
  6. Motlagh, A.M.; Yang, Z. Detection and occurrence of indicator organisms and pathogens. Water Environ. Res. 2019, 91, 1402–1408. [Google Scholar] [CrossRef]
  7. Kaper, J.B.; Nataro, J.P.; Mobley, H.L. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2004, 2, 123–140. [Google Scholar] [CrossRef] [PubMed]
  8. Nyirabahizi, E.; Tyson, G.H.; Dessai, U.; Zhao, S.; Kabera, C.; Crarey, E.; Womack, N.; Crews, M.K.; Strain, E.; Tate, H. Evaluation of Escherichia coli as an indicator for antimicrobial resistance in Salmonella recovered from the same food or animal ceca samples. Food Control. 2020, 115, 107280. [Google Scholar] [CrossRef]
  9. Al-Tamimi, M.; Abu-Raideh, J.; Albalawi, H.; Shalabi, M.; Saleh, S. Effective oral combination treatment for extended-spectrum beta-lactamase-producing Escherichia coli. Microb. Drug Resist. 2019, 25, 1132–1141. [Google Scholar] [CrossRef]
  10. Ezure, Y.; Rico, V.; Paterson, D.L.; Hall, L.; Harris, P.N.A.; Soriano, A.; Roberts, J.A.; Bassetti, M.; Roberts, M.J.; Righi, E.; et al. Efficacy and safety of carbapenems vs. new antibiotics for treatment of adult patients with complicated urinary tract infections: A systematic review and meta-analysis. Open Forum Infect. Dis. 2020, 9, ofaa480. [Google Scholar] [CrossRef]
  11. Sherchan, J.B.; Hayakawa, K.; Miyoshi-Akiyama, T.; Ohmagari, N.; Kirikae, T.; Nagamatsu, M.; Tojo, M.; Ohara, H.; Sherchand, J.B.; Tandukar, S. Clinical epidemiology, and molecular analysis of extended-spectrum-β-lactamase-producing Escherichia coli in Nepal: Characteristics of sequence types 131 and 648. Antimicrob. Agents Chemother. 2015, 59, 3424–3432. [Google Scholar] [CrossRef]
  12. Nicolas-Chanoine, M.H.; Bertrand, X.; Madec, J.Y. Escherichia coli ST131, an intriguing clonal group. Clin. Microbiol. Rev. 2014, 27, 543–574. [Google Scholar] [CrossRef] [PubMed]
  13. Schaufler, K.; Semmler, T.; Pickard, D.J.; de Toro, M.; de la Cruz, F.; Wieler, L.H.; Ewers, C.; Guenther, S. Carriage of extended-spectrum beta-lactamase-plasmids does not reduce fitness but enhances virulence in some strains of pandemic E. coli lineages. Front. Microbiol. 2016, 7, 336. [Google Scholar] [CrossRef] [PubMed]
  14. Redha, M.A.; Al Sweih, N.; Albert, M.J. Virulence and phylogenetic groups of Escherichia coli cultured from raw sewage in Kuwait. Gut Pathog. 2022, 14, 18. [Google Scholar] [CrossRef] [PubMed]
  15. Manges, A.R.; Geum, H.M.; Guo, A.; Edens, T.J.; Fibke, C.D.; Pitout, J.D.D. Global extraintestinal pathogenic Escherichia coli (ExPEC) lineages. Clin. Microbiol. Rev. 2019, 32, e00135-18. [Google Scholar] [CrossRef]
  16. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing (M100), 28th ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2018. [Google Scholar]
  17. Magiorakos, A.-P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant, and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012, 18, 268–281. [Google Scholar] [CrossRef]
  18. European Committee on Antibiotic Susceptibility Testing (EUCAST). Available online: http://www.eucast.org (accessed on 5 May 2022).
  19. Nordmann, P.; Jayol, A.; Poirel, L. Rapid detection of polymyxin resistance in Enterobacteriaceae. Emerg. Infect. Dis. 2016, 22, 1038–1043. [Google Scholar] [CrossRef]
  20. Hubney, J.; Ciesielski, S.; Harnisz, M.; Korzeniewska, E.; Dulski, T.; Jalowiecki, L.; Plaza, G. Genes during wastewater treatment with an emphasis on carbapenemase genes: A metagenomic approach. Front. Environ. Sci. 2021, 9, 738158. [Google Scholar] [CrossRef]
  21. Cui, X.; Zhang, H.; Du, H. Carbapenemases in Enterobacteriaceae: Detection and antimicrobial therapy. Front. Microbiol. 2019, 10, 1823. [Google Scholar] [CrossRef]
  22. Center for Disease Control and Prevention. Health-Care-Associated Infections. Available online: https://www.hhs.gov/oidp/topics/health-care-associated-infections/index.html (accessed on 11 August 2023).
  23. Dortet, L.; Poirel, L.; Nordmann, P. Rapid detection of ESBL-producing Enterobacteriaceae in blood cultures. Emerg. Infect. Dis. 2015, 21, 504–507. [Google Scholar] [CrossRef]
  24. Jamal, W.; Rotimi, V.O.; Albert, M.J.; Khodakhast, F.; Nordmann, P.; Poirel, L. High prevalence of VIM-4 and NDM-1 metallo-β-lactamase among carbapenem-resistant Enterobacteriaceae. J. Med. Microbiol. 2013, 62, 1239–1244. [Google Scholar] [CrossRef]
  25. Al Fadhli, A.; Jamal, W.; Rotimi, V.O. Molecular characterization of rectal isolates of carbapenemase-negative carbapenem-resistant enterobacteriales obtained from ICU patients in Kuwait by whole genome sequencing. J. Med. Microbiol. 2021, 70, 001409. [Google Scholar] [CrossRef]
  26. Doumith, M.; Day, M.; Ciesielczuk, H.; Hope, R.; Underwood, A.; Reynolds, R.; Wain, J.; Livermore, D.M.; Woodford, N. Rapid identification of major Escherichia coli sequence types causing urinary tract and bloodstream infections. J. Clin. Microbiol. 2015, 53, 160–166. [Google Scholar] [CrossRef]
  27. Johnson, J.R.; Johnston, B.D.; Gordon, D.M. Rapid and specific detection of the Escherichia coli sequence type 648 complex within phylogroup F. J. Clin. Microbiol. 2017, 55, 1116–1121. [Google Scholar] [CrossRef] [PubMed]
  28. Naidoo, S.; Olaniran, A.O. Treated wastewater effluent as a source of microbial pollution of surface water resources. Int. J. Environ. Res. Public Health 2013, 11, 249–270. [Google Scholar] [CrossRef] [PubMed]
  29. Al Benwan, K.; Al Sweih, N.; Rotimi, V.O. Etiology and antibiotic susceptibility patterns of community- and hospital-acquired urinary tract infections in a general hospital in Kuwait. Med. Princ. Pract. 2010, 19, 440–446. [Google Scholar] [CrossRef]
  30. Al Sweih, N.; Al Hashem, G.; Jamal, W.; Rotimi, V. National surveillance of antimicrobial susceptibility of CTX-M-positive and -negative clinical isolates of Escherichia coli from Kuwait government hospitals. J. Chemother. 2010, 22, 254–258. [Google Scholar] [CrossRef] [PubMed]
  31. Sewify, M.; Nair, S.; Warsame, S.; Murad, M.; Alhubail, A.; Behbehani, K.; Al-Refaei, F.; Tiss, A. Prevalence of urinary tract infection and antimicrobial susceptibility among diabetic patients with controlled and uncontrolled glycemia in Kuwait. J. Diabetes Res. 2016, 2016, 6573215. [Google Scholar] [CrossRef] [PubMed]
  32. Alfouzan, W.; Dhar, R.; Nicolau, D.P. In vitro activity of newer and conventional antimicrobial agents, including fosfomycin and colistin, against selected Gram-negative bacilli in Kuwait. Pathogens 2018, 7, 75. [Google Scholar] [CrossRef]
  33. Available online: https://www.tdlpathology.com/specialties/medical-microbiology/new-high-dose-antibiotic-susceptibility-category/ (accessed on 15 October 2023).
  34. Torumkuney, D.; Behbehani, N.; Hasselt, J.; Hamouda, M.; Keles, N. Country data on AMR in Kuwait in the context of community-acquired respiratory tract infections: Links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicines and clinical outcome. J. Antimicrob. Chemother. 2022, 77 (Suppl. S1), i77–i83. [Google Scholar] [CrossRef]
  35. Livermore, D.M. beta-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 1995, 8, 557–584. [Google Scholar] [CrossRef]
  36. Caroff, N.; Espaze, E.; Bérard, I.; Richet, H.; Reynaud, A. Mutations in the ampC promoter of Escherichia coli isolates resistant to oxyiminocephalosporins without extended spectrum beta-lactamase production. FEMS Microbiol. Lett. 1999, 173, 459–465. [Google Scholar] [CrossRef] [PubMed]
  37. Jacoby, G.A. AmpC beta-lactamases. Clin. Microbiol. Rev. 2009, 161–182. [Google Scholar] [CrossRef] [PubMed]
  38. Dortet, L.; Poirel, L.; Nordmann, P. Rapid detection of extended-spectrum-β-lactamase-producing enterobacteriaceae from urine samples by use of the ESBL NDP test. J. Clin. Microbiol. 2014, 52, 3701–3706. [Google Scholar] [CrossRef]
  39. Dashti, A.A.; Vali, L.; Jadaon, M.M.; El-Shazly, S.; Amyes, S.G. The emergence of carbapenem resistance in ESBL-producing E. coli 025B-ST131 strain from community acquired infection in Kuwait. BMC Proc. 2011, 5, 027. [Google Scholar] [CrossRef]
  40. Al Fadhli, A.H.; Jamal, W.Y.; Rotimi, V.O. Prevalence of carbapenem-resistant Enterobacteriaceae and emergence of high rectal colonization rates of blaOXA-181-positive isolates in patients admitted to two major hospital intensive care units in Kuwait. PLoS ONE 2020, 15, e0241971. [Google Scholar] [CrossRef]
  41. Moghnia, O.H.; Rotimi, V.O.; Al-Sweih, N.A. Preponderance of blaKPC-carrying carbapenem-resistant enterobacterales among fecal isolates from community food handlers in Kuwait. Front. Microbiol. 2021, 12, 737828. [Google Scholar] [CrossRef]
  42. Nordmann, P.; Naas, T.; Poirel, L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 2011, 17, 1791–1798. [Google Scholar] [CrossRef]
  43. Cantón, R.; Akóva, M.; Carmeli, Y.; Giske, C.; Glupczynski, Y.; Gniadkowski, M.; Livermore, D.; Miriagou, V.; Naas, T.; Rossolini, G.; et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 2012, 18, 413–431. [Google Scholar] [CrossRef]
  44. Falagas, M.E.; Tansarli, G.S.; Karageorgopoulos, D.E.; Vardakas, K.Z. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg. Infect. Dis. 2014, 20, 1170–1175. [Google Scholar] [CrossRef]
  45. Zowawi, H.M.; Sartor, A.L.; Balkhy, H.H.; Walsh, T.R.; Al Johani, S.M.; Aljindan, R.Y.; Alfaresi, M.; Ibrahim, E.; Al-Jardani, A.; Al-Abri, S.; et al. Molecular characterization of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in the countries of the Gulf Cooperation Council: Dominance of OXA-48 and NDM producers. Antimicrob. Agents Chemother. 2014, 58, 3085–3090. [Google Scholar] [CrossRef]
  46. Poirel, L.; Nordmann, P. Rapidec Carba NP Test for rapid detection of carbapenemase producers. J. Clin. Microbiol. 2015, 53, 3003–3008. [Google Scholar] [CrossRef]
  47. Chetri, S.; Bhowmik, D.; Paul, D.; Pandey, P.; Chanda, D.D.; Chakravarty, A.; Bora, D.; Bhattacharjee, A. AcrAB-TolC efflux pump system plays a role in carbapenem non-susceptibility in Escherichia coli. BMC Microbiol. 2019, 19, 210. [Google Scholar] [CrossRef] [PubMed]
  48. Stapleton, P.D.; Shannon, K.P.; French, G.L. Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 beta-lactamase production and loss of an outer membrane protein. Antimicrob. Agents Chemother. 1999, 43, 1206–1210. [Google Scholar] [CrossRef] [PubMed]
  49. Kong, H.-K.; Pan, Q.; Lo, W.-U.; Liu, X.; Law, C.O.K.; Chan, T.-F.; Ho, P.-L.; Lau, T.C.-K. Fine-tuning carbapenem resistance by reducing porin permeability of bacteria activated in the selection process of conjugation. Sci. Rep. 2018, 8, 15248. [Google Scholar] [CrossRef] [PubMed]
  50. Cardonha, A.M.; Vieira, R.H.; Rodrigues, D.P.; Macrae, A.; Peirano, G.; Teophilo, G.N. Fecal pollution in water from storm sewers and adjacent seashores in Natal, Rio Grande do Norte, Brazil. Int. Microbiol. 2004, 7, 213–218. [Google Scholar]
  51. Oliveira, K.W.; Gomes, F.C.O.; Benko, G.; Pimenta, R.S.; Magalhaes, P.P.; Mendes, E.N.; Morais, P.B. Antimicrobial resistance profiles of diarrheagenic Escherichia coli strains isolated from bathing waters of the Lajeado reservoir in Tocantins, Brazil. Rev. Ambient. Água. 2012, 7, 30. [Google Scholar] [CrossRef]
  52. Ramírez Castillo, F.Y.; Avelar González, F.J.; Garneau, P.; Márquez Díaz, F.; Guerrero Barrera, A.L.; Harel, J. Presence of multi-drug resistant pathogenic Escherichia coli in the San Pedro River located in the State of Aguascalientes, Mexico. Front. Microbiol. 2013, 4, 147. [Google Scholar] [CrossRef]
  53. Adefisoye, M.A.; Okoh, A.I. Identification and antimicrobial resistance prevalence of pathogenic Escherichia coli strains from treated wastewater effluents in Eastern Cape, South Africa. Microbiologyopen 2016, 5, 143–151. [Google Scholar] [CrossRef]
  54. Lau, S.H.; Kaufmann, M.E.; Livermore, D.M.; Woodford, N.; Willshaw, G.A.; Cheasty, T.; Stamper, K.; Reddy, S.; Cheesbrough, J.; Bolton, F.J.; et al. UK epidemic Escherichia coli strains A-E, with CTX-M-15 beta-lactamase, all belong to the international O25:H4-ST131 clone. J. Antimicrob. Chemother. 2008, 62, 1241–1244. [Google Scholar] [CrossRef]
  55. Pitout, J.D.; Gregson, D.B.; Campbell, L.; Laupland, K.B. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: Emergence of clone ST131 as a cause of community-acquired infections. Antimicrob. Agents Chemother. 2009, 53, 2846–2851. [Google Scholar] [CrossRef]
  56. Johnson, J.R.; Johnston, B.; Clabots, C.; Kuskowski, M.A.; Castanheira, M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin. Infect. Dis. 2010, 51, 286–294. [Google Scholar] [CrossRef]
  57. Dahbi, G.; Mora, A.; López, C.; Alonso, M.P.; Mamani, R.; Marzoa, J.; Coira, A.; García-Garrote, F.; Pita, J.M.; Velasco, D.; et al. Emergence of new variants of ST131 clonal group among extraintestinal pathogenic Escherichia coli producing extended-spectrum β-lactamases. Int. J. Antimicrob. Agents 2013, 42, 347–351. [Google Scholar] [CrossRef] [PubMed]
  58. Jørgensen, S.B.; Søraas, A.V.; Arnesen, L.S.; Leegaard, T.M.; Sundsfjord, A.; Jenum, P.A. A comparison of extended spectrum β-lactamase producing Escherichia coli from clinical, recreational water and wastewater samples associated in time and location. PLoS ONE 2017, 12, e0186576. [Google Scholar] [CrossRef] [PubMed]
  59. Mora, A.; Herrera, A.; Mamani, R.; López, C.; Alonso, M.P.; Blanco, J.E.; Blanco, M.; Dahbi, G.; Garciía-Garrote, F.; Pita, J.M.; et al. Recent emergence of clonal group O25b:K1:H4-B2-ST131 ibeA strains among Escherichia coli poultry isolates, including CTX-M-9-producing strains, and comparison with clinical human isolates. Appl. Environ. Microbiol. 2010, 76, 6991–6997. [Google Scholar] [CrossRef]
  60. Jouini, A.; Klibi, A.; Elarbi, I.; Ben Chaabene, M.; Hamrouni, S.; Souiai, O.; Hanachi, M.; Ghram, A.; Maaroufi, A. First detection of human ST131-CTX-M-15-O25-B2 clone and high-risk clonal lineages of ESBL/pAmpC-producing E. coli isolates from diarrheic poultry in Tunisia. Antibiotics 2021, 10, 670. [Google Scholar] [CrossRef]
  61. Khoshbayan, A.; Golmoradi Zadeh, R.; Taati Moghadam, M.; Mirkalantari, S.; Darbandi, A. Molecular determination of O25b/ST131 clone type among extended spectrum β-lactamases production Escherichia coli recovering from urinary tract infection isolates. Ann. Clin. Microbiol. Antimicrob. 2022, 21, 35. [Google Scholar] [CrossRef]
  62. Blanco, M.; Alonso, M.P.; Nicolas-Chanoine, M.-H.; Dahbi, G.; Mora, A.; Blanco, J.E.; López, C.; Cortés, P.; Llagostera, M.; Leflon-Guibout, V.; et al. Molecular epidemiology of Escherichia coli producing extended-spectrum {beta}-lactamases in Lugo (Spain): Dissemination of clone O25b:H4-ST131 producing CTX-M-15. J. Antimicrob. Chemother. 2009, 63, 1135–1141. [Google Scholar] [CrossRef] [PubMed]
  63. De La Cadena, E.; Mojica, M.F.; Castillo, N.; Correa, A.; Appel, T.M.; García-Betancur, J.C.; Pallares, C.J.; Villegas, M.V. Genomic analysis of CTX-M-group-1-producing extraintestinal pathogenic E. coli (ExPEC) from patients with urinary tract infections (UTI) from Colombia. Antibiotics 2020, 9, 899. [Google Scholar] [CrossRef]
  64. Ranjan, A.; Scholz, J.; Semmler, T.; Wieler, L.H.; Ewers, C.; Müller, S.; Pickard, D.J.; Schierack, P.; Tedin, K.; Ahmed, N.; et al. ESBL-plasmid carriage in E. coli enhances in vitro bacterial competition fitness and serum resistance in some strains of pandemic sequence types without overall fitness cost. Gut Pathog. 2018, 10, 24. [Google Scholar] [CrossRef]
  65. Dashti, A.A.; Vali, L.; El-Shazly, S.; Jadaon, M.M. The characterization and antibiotic resistance profiles of clinical Escherichia coli O25b-B2-ST131 isolates in Kuwait. BMC Microbiol. 2014, 14, 214. [Google Scholar] [CrossRef]
  66. Fernandes, M.R.; Sellera, F.P.; Moura, Q.; Gaspar, V.C.; Cerdeira, L.; Lincopan, N. International high-risk clonal lineages of CTX-M-producing Escherichia coli F-ST648 in free-roaming cats, South America. Infect. Genet. Evol. 2018, 66, 48–51. [Google Scholar] [CrossRef]
  67. Guenther, S.; Ewers, C.; Wieler, L.H. Extended-spectrum beta-lactamases producing E. coli in wildlife, yet another form of environmental pollution? Front. Microbiol. 2011, 2, 246. [Google Scholar] [CrossRef] [PubMed]
  68. Mathers, A.J.; Peirano, G.; Pitout, J.D. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin. Microbiol. Rev. 2015, 28, 565–591. [Google Scholar] [CrossRef]
  69. Ortega-Paredes, D.; Barba, P.; Mena-López, S.; Espinel, N.; Zurita, J. Escherichia coli hyperepidemic clone ST410-A harboring blaCTX-M-15 isolated from fresh vegetables in a municipal market in Quito-Ecuador. Int. J. Food Microbiol. 2018, 280, 41–45. [Google Scholar] [CrossRef] [PubMed]
  70. Zahra, R.; Javeed, S.; Malala, B.; Babenko, D.; Toleman, M.A. Analysis of Escherichia coli STs and resistance mechanisms in sewage from Islamabad, Pakistan indicates a difference in E. coli carriage types between South Asia and Europe. J. Antimicrob. Chemother. 2018, 73, 1781–1785. [Google Scholar] [CrossRef] [PubMed]
  71. Guzman-Otazo, J.; Gonzales-Siles, L.; Poma, V.; Bengtsson-Palme, J.; Thorell, K.; Flach, C.-F.; Iñiguez, V.; Sjöling, Å. Diarrheal bacterial pathogens and multi-resistant enterobacteria in the Choqueyapu River in La Paz, Bolivia. PLoS ONE 2019, 14, e0210735. [Google Scholar] [CrossRef]
  72. Paulshus, E.; Thorell, K.; Guzman-Otazo, J.; Joffre, E.; Colque, P.; Kühn, I.; Möllby, R.; Sørum, H.; Sjöling, Å. Repeated isolation of extended-spectrtum-β-lactamase-positive Escherichia coli sequence types 648 and 131 from community wastewater indicates that sewage systems are important sources of emerging clones of antibiotic-resistant bacteria. Antimicrob. Agents Chemother. 2019, 63, e00823-19. [Google Scholar] [CrossRef] [PubMed]
  73. Toner, E.; Adalja, A.; Gronvall, G.K.; Cicero, A.; Inglesby, T.V. Antimicrobial resistance is a global health emergency. Health Secur. 2015, 13, 153–155. [Google Scholar] [CrossRef]
  74. Council of Scientific and Industrial Research Organisation (CSIRO). Available online: https://www.csiro.au/en/news/all/news/2022/april/csiro-study-finds-antimicrobial-resistance-is-making-utis-more-deadly (accessed on 4 October 2022).
  75. Khan, S.N.; Khan, A.U. Breaking the spell: Combating multidrug-resistant ‘superbugs’. Front. Microbiol. 2016, 7, 174. [Google Scholar] [CrossRef]
  76. Parker, E.N.; Cain, B.N.; Hajian, B.; Ulrich, R.J.; Geddes, E.J.; Barkho, S.; Lee, H.Y.; Williams, J.D.; Raynor, M.; Caridha, D.; et al. An iterative approach guides discovery of the FabI inhibitor fabimycin, a late-stage antibiotic candidate with in vivo efficacy against drug-resistant Gram-negative infections. ACS Cent. Sci. 2022, 8, 1145–1158. [Google Scholar] [CrossRef]
  77. Shukla, R.; Lavore, F.; Maity, S.; Derks, M.G.N.; Jones, C.R.; Vermeulen, B.J.A.; Melcrová, A.; Morris, M.A.; Becker, L.M.; Wang, X.; et al. Teixobactin kills bacteria by a two-pronged attack on the cell envelope. Nature 2022, 608, 390–396. [Google Scholar] [CrossRef] [PubMed]
  78. Centers for Disease Control and Prevention. One Health Basics. CDC 24/7. Saving Lives, Protecting People, 28 September 2023. Available online: https://www.cdc.gov/onehealth/who-we-are/one-health-office-fact-sheet.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fonehealth%2Fmultimedia%2Ffactsheet.html (accessed on 15 October 2023).
  79. Fernando, D.M.; Tun, H.M.; Poole, J.; Patidar, R.; Li, R.; Mi, R.; Amarawansha, G.E.A.; Fernando, W.G.D.; Khafipour, E.; Farenhorst, A.; et al. Detection of antibiotic resistance genes in source and drinking water samples from a First Nations community in Canada. Appl. Environ. Microbiol. 2016, 82, 4767–4775. [Google Scholar] [CrossRef] [PubMed]
Table 1. Susceptibility and resistance of 140 E. coli isolates to various antimicrobial agents.
Table 1. Susceptibility and resistance of 140 E. coli isolates to various antimicrobial agents.
Antimicrobial AgentsNo. of Isolates with Indicated Resistance
Resistant (R)Intermediate Resistance (IR) aSusceptible (S)
Cefepime244670
Cephalothin92399
Ceftazidime293873
Cefoxitin1119110
Cefotaxime774221
Ceftriaxone271598
Aztreonam241799
Ertapenem31136
Meropenem20138
Imipenem110129
Gentamicin52133
Streptomycin483062
Amikacin614120
Amoxiclav 631859
Ampicillin/Sulbactam262490
Piperacillin/Tazobactam205565
Ampicillin852233
Piperacillin883022
Trimethoprim59180
Co-Trimoxazole57182
Tetracycline661559
Ciprofloxacin222494
Fosfomycin22136
Azithromycin130127
Chloramphenicol216113
Sulfafurazole58874
Polymyxin B b25NA115
Colistin b4NA136
a In the counting of resistant strains, R and IR strains were merged. b Susceptibility to polymyxin B and colistin was measured by rapid polymyxin NP test for which the IR category is not applicable (NA).
Table 2. Resistance a of 140 E. coli isolates to number of antibiotics and their classes.
Table 2. Resistance a of 140 E. coli isolates to number of antibiotics and their classes.
Resistance to Antibiotic and Antibiotic ClassNo. of Isolates
Resistance to no. of Antibiotic(s)No. of Isolates
02
12
22
38
46
58
610
78
88
98
107
118
1212
1312
1410
1512
165
175
183
191
201
221
231
Resistance to no. of antibiotic class(s)No. of isolates
02
13
25
312
413
515
615
713
817
918
1015
117
123
131
141
a Include both resistant and intermediate-resistance isolates.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Redha, M.A.; Al Sweih, N.; Albert, M.J. Multidrug-Resistant and Extensively Drug-Resistant Escherichia coli in Sewage in Kuwait: Their Implications. Microorganisms 2023, 11, 2610. https://doi.org/10.3390/microorganisms11102610

AMA Style

Redha MA, Al Sweih N, Albert MJ. Multidrug-Resistant and Extensively Drug-Resistant Escherichia coli in Sewage in Kuwait: Their Implications. Microorganisms. 2023; 11(10):2610. https://doi.org/10.3390/microorganisms11102610

Chicago/Turabian Style

Redha, Mahdi A., Noura Al Sweih, and M. John Albert. 2023. "Multidrug-Resistant and Extensively Drug-Resistant Escherichia coli in Sewage in Kuwait: Their Implications" Microorganisms 11, no. 10: 2610. https://doi.org/10.3390/microorganisms11102610

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop